XML 39 R29.htm IDEA: XBRL DOCUMENT
v3.25.1

Revenue from Contracts with Customers (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Schedule of Provisions for Sales and Allowances | A rollfor ward of the Company’s provisions for sales discounts and allowances is as follows:
|  | March 31, 2025 |
(In thousands) |  | Contractual Adjustments(1) |  |  | Discounts(2) |  |  | Product Returns |  |  | Other |  |  | Total |
Beginning balance — December 31, 2024 |  | $ | 228,978 |  |  | $ | 43,645 |  |  | $ | 50,507 |  |  | $ | 13,297 |  |  | $ | 336,427 |
Current provisions relating to sales in current year |  |  | 123,300 |  |  |  | 91,264 |  |  |  | 6,392 |  |  |  | 19,543 |  |  |  | 240,499 |
Adjustments relating to prior years |  |  | (11,311 | ) |  |  | — |  |  |  | (901 | ) |  |  | — |  |  |  | (12,212 | )
Payments relating to sales in current year |  |  | (5,713 | ) |  |  | (81,201 | ) |  |  | — |  |  |  | (11,839 | ) |  |  | (98,753 | )
Payments relating to sales in prior years |  |  | (120,893 | ) |  |  | (20,793 | ) |  |  | (3,087 | ) |  |  | (11,244 | ) |  |  | (156,017 | )
Ending balance — March 31, 2025 |  | $ | 214,361 |  |  | $ | 32,915 |  |  | $ | 52,911 |  |  | $ | 9,757 |  |  | $ | 309,944 |
1. “Contractual Adjustments” include “Medicaid Rebates” and “Medicare Part D” accruals 2. “Discounts” in clude “Chargebacks” and “Product Discounts”
Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets | Total revenue-related reserves as of March 31, 2025 and December 31, 2024 included in the accompanying consolidated balance sheets are summarized as follows:
|  | March 31, |  |  | December 31, |
(In thousands) |  | 2025 |  |  | 2024 |
Reduction of accounts receivable |  | $ | 14,993 |  |  | $ | 22,031 |
Components of accrued sales discounts, allowances and reserves |  |  | 249,795 |  |  |  | 272,452 |
Components of other long-term liabilities |  |  | 45,156 |  |  |  | 41,944 |
Total revenue-related reserves |  | $ | 309,944 |  |  | $ | 336,427 |
Schedule of Contract Assets and Contract Liabilities | Total contract assets at March 31, 2025 were as follows:
(In thousands) |  | Contract Assets |
Contract assets at December 31, 2024 |  | $ | 4,990 |
Additions |  |  | 3,049 |
Transferred to receivables, net |  |  | (4,990 | )
Contract assets at March 31, 2025 |  | $ | 3,049 |
Total contract liabilities at March 31, 2025 were as follows:
(In thousands) |  | Contract Liabilities |
Contract liabilities at December 31, 2024 |  | $ | 1,249 |
Additions |  |  | 1,313 |
Amounts recognized into revenue |  |  | (953 | )
Contract liabilities at March 31, 2025 |  | $ | 1,609 |
Product sales, net |
Schedule of Disaggregation of Revenues | During the three months ended March 31, 2025 and 2024, the Company recorded product sales, net, as follows:
|  | Three Months Ended March 31, |
(In thousands) |  | 2025 |  |  | 2024 |
VIVITROL |  |  | 100,996 |  |  | $ | 97,659 |
ARISTADA and ARISTADA INITIO |  |  | 73,475 |  |  |  | 78,870 |
LYBALVI |  |  | 70,022 |  |  |  | 57,007 |
Total product sales, net |  | $ | 244,493 |  |  | $ | 233,536 |
Manufacturing and royalty revenues |
Schedule of Disaggregation of Revenues | During the three months ended March 31, 2025 and 2024, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|  | Three Months Ended March 31, 2025 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 17,745 |  |  | $ | 17,745 |
VUMERITY |  |  | 5,975 |  |  |  | 21,858 |  |  |  | 27,833 |
RISPERDAL CONSTA |  |  | 9,115 |  |  |  | 14 |  |  |  | 9,129 |
Other |  |  | 2,237 |  |  |  | 5,073 |  |  |  | 7,310 |
|  | $ | 17,327 |  |  | $ | 44,690 |  |  | $ | 62,017 |
|  | Three Months Ended March 31, 2024 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 62,673 |  |  | $ | 62,673 |
VUMERITY |  |  | 12,124 |  |  |  | 19,130 |  |  |  | 31,254 |
RISPERDAL CONSTA |  |  | 2,595 |  |  |  | 124 |  |  |  | 2,719 |
Other |  |  | 15,311 |  |  |  | 4,876 |  |  |  | 20,187 |
|  | $ | 30,030 |  |  | $ | 86,803 |  |  | $ | 116,833 |
(1) “long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X
- Definition Revenue related reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | alks_RevenueRelatedReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | alks_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |